Table 3.
Anti-influenza virus activity and cytotoxicity of selected compounds in MDCK cells.
| ||||
|---|---|---|---|---|
|
EC50
a
values (μM) towards influenza viruses
|
||||
| Compounds. | R | H1N1 c | H3N2 d | CC50 (μM) b |
| group-1 | group-2 | |||
| 6g |
|
0.03 ± 0.03 | 0.16 ± 0.08 | >250 |
| 6i |
|
0.03 ± 0.03 | 0.32 ± 0.08 | >250 |
| 6j |
|
0.03 ± 0.02 | 0.80 ± 0.003 | >250 |
| 6k |
|
0.02 ± 0.01 | 0.12 ± 0.03 | >250 |
| OSC | – | 0.02 ± 0.01 | 0.36 ± 0.16 | >250 |
| ZA | – | 0.009 ± 0.002 | 0.27 ± 0.03 | >250 |
aEC50: compound concentration that inhibits 50% of virus plaque formation in MDCK cells infected with influenza A viral strains, presented as the mean ± SD and determined by the PRA method.
bCC50: concentration required to reduce the viability of mock-infected cell cultures by 50%, as determined by the MTT method.
cA/PR/8/34.
dA/Wisconsin/67/05.